iRhythm Holdings

IRTC · NASDAQ

$113.85+$4.25 (+3.88%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $109.60

IRTC analyst rating

BuyConsensus of 15 analysts over the last 12 months. 93% rate it a buy.

Strong buy0
Buy14
Hold1
Underperform0
Sell0

12-month price target · 16 analysts

Average $179.76 (+57.9% upside)

Low: $158.57
Now: $113.85
High: $205.80

Upgrades and downgrades

The latest rating actions, newest first

IRTC analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Piper Sandler	Oct 16, 2026	Initiates	Overweight	$160.00	51%
Wells Fargo	Oct 6, 2026	Maintains	Overweight	$168.00 → $150.00	19%
Freedom Capital Markets	Oct 6, 2026	Maintains	Buy	$190.00	64%
Needham	Oct 5, 2026	Maintains	Buy	$192.00 → $194.00	39%
Wells Fargo	Aug 18, 2026	Maintains	Overweight	$180.00 → $168.00	19%
Truist Securities	Aug 10, 2026	Maintains	Buy	$160.00 → $168.00	50%
Wells Fargo	Aug 7, 2026	Maintains	Overweight	$180.00 → $168.00	19%
Needham	Aug 7, 2026	Maintains	Buy	$255.00 → $192.00	39%
Evercore ISI Group	Aug 7, 2026	Maintains	Outperform	$150.00 → $165.00	52%
Stephens & Co.	Jul 23, 2026	Initiates	Overweight	$160.00	51%

The case for and against

Updated Oct 14, 2026

Bull case

iRhythm Holdings is viewed positively because its Zio platform combines a wire-free, 14-day wearable biosensor with proprietary cloud analytics, creating a differentiated, scalable solution that can improve physician workflow and patient diagnosis while supporting continued volume growth. Recent performance reinforces that thesis, with revenue of $224.2M up 20.1% year over year, gross margin of 72.8%, and adjusted EBITDA of $43.3M at a 19.3% margin, showing both operating leverage and disciplined execution. Longer term, the company’s 2027 outlook calls for revenue above $1B and greater than 70% gross margin, while the VitalConnect acquisition should expand its addressable market, add at least $65M in next 12-month revenue, and strengthen its competitive position in ambulatory cardiac monitoring.

Bear case

iRhythm Holdings is facing a deteriorating fundamental setup because the DOJ Civil Investigative Demand and the June 2023 FDA warning letter together create regulatory uncertainty that could weigh on Zio AT reimbursement, commercialization, and investor confidence. Reimbursement risk is also substantial, as the company faces scrutiny over rate reductions, prior authorization, coverage limitations, and managed care pressure, while rising competition from larger device firms and emerging entrants threatens market share and execution. Even if the CID is ultimately resolved with a manageable settlement, the unresolved FDA issues, potential adverse settlement terms, and the risk of underwhelming product launches or an additional equity offering keep the outlook negative.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.